Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.75 |
| ▸ | KDR | P35968 | 3/20 | 0.75 |
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 1/20 | 0.75 |
| ▸ | INSR | P06213 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | FLT4 | P35916 | 1/20 | 0.75 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.75 |
| ▸ | TEK | Q02763 | 1/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.67 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28549001 | 0.99 | EGFR (0.74) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL23959897 | 0.91 | EGFR (0.77) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL30362898 | 0.91 | EGFR (0.70) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL27667251 | 0.89 | EGFR (0.62) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL8215639 | 0.89 | EGFR (0.74) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL27686218 | 0.88 | EGFR (0.60) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL27686261 | 0.87 | EGFR (0.60) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL2099106 | 0.86 | EGFR (1.00) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL30505605 | 0.86 | EGFR (1.00) | EGFRERBB2KDRFBP1AURKA | |
| Hydrochloric Acid SCHEMBL27887194 | 0.85 | EGFR (0.98) | EGFRERBB2KDRFBP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | EGFR 41/4885ERBB2 8/4885KDR 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.